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HIV-1 utilizes tRNALys,3 as the primer for initiation of reverse transcription. To further examine the tRNA sequence and structural
requirements for primer selection, we developed a complementation system which required tRNALys to be provided in trans. We constructed an
HIV-1 provirus in which the primer-binding site (PBS) was altered to be complementary to the 3′ terminal 18-nucleotides of E. coli tRNALys,3,
which shares many bases with mammalian tRNALys,3, and demonstrated that infectious virus was obtained only if the provirus was co-transfected
with the plasmid encoding E. coli tRNALys,3. In the current study we have mutated E. coli tRNALys,3 so that nucleotides within the stem of the
anticodon stem–loop were made identical to mammalian tRNALys,3. Analysis of the complementation revealed that the modified E. coli tRNALys,3
(E. coli tRNALys,3-MA) complemented 3–5 times more efficiently than E. coli tRNALys,3. Mutation of nucleotides within the anticodon stem
region of E. coli tRNALys,3-MA that differed from E. coli tRNALys,3 revealed the importance of the nucleotide sequence for efficient use in reverse
transcription. The results of our studies highlight that multiple regions of mammalian tRNALys,3 are important for the preference of tRNALys,3 as
the primer for HIV-1 reverse transcription.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV; tRNA; Primer binding site; Reverse transcriptionIntroduction
Human immunodeficiency type 1 (HIV-1), like most
lentiviruses, exclusively selects tRNALys,3 as the primer for
reverse transcription (Mak et al., 1997; Marquet et al., 1995).
Previous studies from this laboratory and others have shown
that HIV-1 has the capacity to select alternative tRNAs as the
primers for reverse transcription (Das et al., 1995; Li et al.,
1994; Wakefield et al., 1995). Alteration of the PBS to be
complementary to numerous tRNAs allows HIV-1 to utilize
these tRNAs for replication. However, the viruses rapidly revert
to utilize tRNALys,3 as the primer for reverse transcription
unless additional mutations are made upstream of the PBS in a
region called the A-loop, which is complementary to the
anticodon of tRNALys,3 (Kang and Morrow, 1999; Kang et al.,⁎ Corresponding author. Fax: +1 205 934 5733.
E-mail address: caseym@uab.edu (C.D. Morrow).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.02.0101997, 1999; Wakefield et al., 1996; Zhang et al., 1998).
Additional regions within the HIV-1 genome have also been
found to potentially be important in primer selection and reverse
transcription. A region (primer activation signal) complemen-
tary to the TΨC stem–loop (nucleotides 50–57) of tRNALys,3 is
located upstream of the PBS in the HIV-1 genome (Beerens et
al., 2001). tRNALys,3 also plays a role in the second strand
transfer during completion of the minus-strand DNA (Brule et
al., 2000). Interaction between tRNALys,3 and U3 during the
first strand transfer of HIV reverse transcription is facilitated by
complementarity between the U3 and nucleotides within the
stem of the tRNALys,3 anticodon RNA stem–loop.
To further understand the mechanism of primer selection, it
would be advantageous to be able to manipulate the tRNA
primer used for reverse transcription. Since it is difficult to
effectively manipulate endogenous levels of tRNA in mamma-
lian cells, previous studies from this laboratory have described a
complementation system in which an exogenous tRNA, yeast
tRNAPhe, was supplied in trans to HIV-1 which had the PBS
mutated to be complementary to the 3′ terminal 18-nucleotides
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Morrow, 2000, 2001). Expression of yeast tRNAPhe from a
cDNA resulted in a tRNA that undergoes aminoacylation,
nuclear transport, and inclusion into the host cell protein
synthesis cycle (Kelly and Morrow, 2005). Using a defined set
of mutants, we were able to ascertain that transport from the
nucleus to the cytoplasm is a key requirement for the tRNA to
be selected as a primer for HIV-1 reverse transcription (Kelly et
al., 2003). Since previous studies have suggested that the reason
for the preferred selection of tRNALys,3 as a primer is due to the
incorporation of lysyl-tRNA synthetase into HIV-1 virions, it
was important to develop a system which more accurately
recapitulated the HIV-1 primer selection process and demon-
strated a preference for tRNALys,3 (Cen et al., 2002; Javanbakht
et al., 2003). To achieve this goal, we engineered an HIV-1 with
a PBS complementary to E. coli tRNALys,3, which maintains
many of the similar features of mammalian tRNALys,3
(McCulley and Morrow, 2006). Using this system, we were
able to demonstrate that HIV-1 replication could be comple-Fig. 1. Mammalian tRNALys,3, E. coli tRNALys,3, and E. coli tRNALys,3-MA. (A) Th
tRNALys,3-MA. The 3′ terminal 18-nucleotides and the anticodon region are outlined
represent base variance between mammalian and E. coli tRNALys,3 sequence. The
tRNALys,3-MA represent nucleotides that have been changed from E. coli tRNALys
tRNALys,3, E. coli tRNALys,3-MA, and E. coli tRNALys,3(A73G). Migration of the am
were collected from 293HEK cells that were transfected with pU6EcLys, pU6EcLys
conditions. Lanes 1 and 2 were loaded with cytoplasmic RNA from pU6EcLys(A73
transfection; lanes 5 and 6 were loaded with cytoplasmic RNA from pU6EcLys trans
transfection. All lanes were probed for E. coli tRNALys,3. DA controls were prepared
in lanes 1, 3, 5, and 7.mented in trans with E. coli tRNALys,3 supplied in the form of a
cDNA. Analysis of E. coli tRNALys,3 anticodon mutants revealed
no correlation between aminoacylation and the ability to
complement, indicating that interactions with the lysyl-tRNA
synthetase do not fully explain the preferential usage of tRNALys,3
as a primer (McCulley and Morrow, 2006).
The level of complementation observed using E. coli
tRNALys,3 was lower to that observed for the yeast tRNAPhe
system, indicating no preferential use of E. coli tRNALys,3
even though this tRNA interacts with lysyl-tRNA synthetase.
To further explore this result in the current study, we have
mutated the cDNA encoding E. coli tRNALys,3 to be identical
to mammalian tRNALys,3 with the exception of the acceptor
stem and the necessary 3′ terminal 18-nucleotides that anneal
with the PBS. We have compared the complementation of E.
coli tRNALys,3 and the modified E. coli tRNALys,3 (tRNALys,3-
MA). Results of our studies demonstrate that tRNALys,3-MA
was approximately 3 to 5-fold more efficient in complementa-
tion than E. coli tRNALys,3 due to nucleotides within thee cloverleaf depiction of mammalian tRNALys,3, E. coli tRNALys,3, and E. coli
in the mammalian tRNALys,3. The boldface nucleotides in the E. coli tRNALys,3
A73G mutation is indicated by an arrow. Circled nucleotides in the E. coli
,3 sequence to mammalian tRNALys,3 sequence. (B) Aminoacylation of E. coli
inoacylated (AA) and deacylated (DA) samples is shown. Cytoplasmic tRNAs
(A73G), and pU6EcLys(MA). All cytoplasmic RNA was isolated under acidic
G) transfection; lanes 7 and 8 were loaded with cytoplasmic RNA from mock
fection; lanes 3 and 4 were loaded with cytoplasmic RNA from pU6EcLys(MA)
by pH adjustment (basic) and incubation for 1 h at 42 °C. DA samples are shown
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results of these studies are discussed with respect to the
preferential selection of tRNALys,3 as the primer for HIV-1
reverse transcription.
Results
In a previous study, we described the construction and
characterization of a complementation system in which E. coli
tRNALys,3 was provided in trans to an HIV-1 genome in which
the PBS was altered to be complementary to the 3′ terminal 18-
nucleotides of E. coli tRNALys,3 (McCulley and Morrow,
2006). While we demonstrated complementation with respect to
production of infectious virus, the level of complementation
was not substantially higher than that found for a similar system
which utilized yeast tRNAPhe and an HIV-1 proviral genome
with the PBS complementary to 3′ terminal 18-nucleotides of
yeast tRNAPhe. Thus, we have not recapitulated the enhanced
preference of HIV-1 for tRNALys,3. Comparison of mammalian
tRNALys,3 with E. coli tRNALys,3 revealed considerable changes
within the anticodon stem region between the two tRNAs. To
determine if alteration of these anticodon stem nucleotides
could enhance the capacity of E. coli tRNALys,3 to complement
the HIV-1 viral genome, we constructed a hybrid E. coli
tRNALys,3 (E. coli tRNALys,3-MA) that consisted of E. coli
tRNALys,3 components (acceptor stem, TΨC stem–loop) and
mammalian tRNALys,3 components (variable loop, anticodon
stem–loop, D stem–loop) (Fig. 1A).
The first step in the characterization of E. coli tRNALys,3-
MA was to determine if it undergoes aminoacylation as E. coli
tRNALys,3. Following transfection, RNA was isolated under
acidic conditions to maintain the integrity of the amino acid–
tRNA bond. The samples were analyzed by gel electrophoresis
and probed for E. coli tRNALys,3. A deaminoacylated control
was obtained by treating a portion of the sample with high pH
buffer to break the amino acid–tRNA bond. We created a
second E. coli tRNALys,3 mutant which contained an A73G
mutation so that the last four nucleotides of E. coli tRNALys,3
would be identical to the last four nucleotides of mammalian
tRNALys,3 (Fig. 1A). The nucleotide at position 73 has also been
implicated as a discriminator base (Huang et al., 1996; Shiba et
al., 1997). Analysis of the samples revealed that all tRNAs were
predominately aminoacylated following expression in mamma-
lian cells (Fig. 1B). Slight differences were observed that could
be attributed to processing given that the amino acid–tRNA
bond is highly heat and pH sensitive. No significant differences
were observed in the intracellular expression of the tRNAs
using a range of plasmid concentrations (data not shown).
Complementation of HIV genomes containing a PBS
complementary to E. coli tRNALys,3
We first compared the capacity of E. coli tRNALys,3 and E.
coli tRNALys,3-MA to complement the HIV-1 proviral genome
containing a PBS complementary to E. coli tRNALys,3 (Fig.
2A). Using a fixed ratio of tRNA plasmids to proviral plasmids,
we generated virus and tested it for infectivity. The amount ofinfectious virus produced is determined following infection of
JC53-BL cells, which encode a luciferase gene positioned
downstream from an HIV-1 LTR. Following infection, the
expression of Tat results in the transcription of luciferase, which
is then detected using a standard assay. Previous studies have
demonstrated that the amount of luciferase produced in the
standard assay correlates with the amount of infectious virus
(McCulley and Morrow, 2006; Wei et al., 2002). In our
complementation system, the production of infectious virus was
dependent upon the co-transfection of the proviral genome and
plasmids encoding E. coli tRNALys,3. Under the standard
conditions, the amount of infectious virus produced by co-
transfection with E. coli tRNALys,3-MAwas approximately 3–5
times to that produced by co-transfection with E. coli tRNALys,3
(Fig. 2B). The amount of virus produced by co-transfection with
E. coli tRNALys,3-MA was comparable to that produced by
transfection of the HXB2 plasmid which relies on the capture of
endogenous mammalian tRNALys,3 for infectivity. Using a
titration of plasmids encoding E. coli tRNALys,3-MA, we found
that the amount of infectious virus produced was greater than
that following co-transfection with E. coli tRNALys,3 over a
wide range of plasmid amounts (Fig. 2C). The increase in the
level of complementation was generally 3–5 times greater for
E. coli tRNALys,3-MA compared to E. coli tRNALys,3. A
mutant E. coli tRNALys,3 with only the A73G mutation alone
did not result in increased production of infectious virus (Fig.
2C). Thus, the A73G mutation, made to correspond to the four
terminal nucleotides of mammalian tRNALys,3 within the 3′
terminal 18-nucleotides of E. coli tRNALys,3, did not enhance
selection and use of E. coli tRNALys,3 (A73G).
Importance of nucleotides with an anticodon stem for
complementation
The major nucleotide differences between E. coli tRNALys-
MA and E. coli tRNALys,3 reside in the anticodon stem (Fig.
1A). Previous studies have shown that the anticodon stem–loop
of tRNALys,3 imparts unique properties with respect to
interaction with codon–anticodon involved in protein synthesis.
Given the fact that the A-loop anticodon interaction has been
suggested to resemble a codon–anticodon interaction, it is
possible that the nucleotides within this stem–loop facilitate this
interaction resulting in the enhanced complementation (Puglisi
and Puglisi, 1998). To investigate this possibility, we made a
series of mutations in the E. coli tRNALys,3 anticodon stem to
determine which would result in enhanced complementation.
The first mutation substituted a U–A base pair at nucleotides
27–43 that were G–U base pair in E. coli tRNALys,3 (Fig. 3A).
This substitution should result in the introduction of aΨ–A base
pair similar to that seen in mammalian tRNALys,3. A second
mutationwas also introduced inwhich a C–G andA–Ubase pair
at nucleotides 28–42 and 29–41 would give a complete stem
sequence of mammalian tRNALys,3 (Fig. 3A). Analysis of tRNA
aminoacylation following transfection revealed that both
mutants were aminoacylated similar to that of E. coli tRNALys,3
and E. coli tRNALys,3-MA (data not shown). The capacity of
these tRNAs to complement the HIV-1 proviral genome with a
Fig. 2. Complementation of HXB2(EcPBSLys) with a plasmid that encodes E. coli tRNALys,3. (A) Diagramatic representation of the proviral U5 region and the
corresponding sequence for wild-type HXB2 and mutant HXB2(EcPBSLys). The underlined sequences correspond to the A-rich region and the PBS. (B) Luciferase
activity obtained from infection of JC53-BL cells with viral supernatants collected from co-transfections of 293HEK cells with 500 ng of HIV-1 proviral plasmids in
the presence or absence of 500 ng of plasmid encoding the specified tRNA, in relation to wild-type HIV-1 (transfected at 500 ng). The data denote means±standard
deviations derived from three independent transfections. (C) Luciferase activity obtained from infection of JC53-BL cells with viral supernatants obtained from co-
transfections of 293HEK cells with 500 ng of proviral plasmids, and tRNA plasmids titrated in at the designated quantities. Luciferase activity, in relative Light Units
per mL (rLU/mL), for complementation of plasmid HXB2(EcPBSLys) with pU6EcLys is represented by open squares (□); for plasmid HXB2(EcPBSLys) with
pU6EcLys-MA is represented by open diamonds (◊); for plasmid HXB2(EcPBSLys) with pU6EcLys(A73G) is represented with closed squares (■). Wild-type HXB2
(500 ng and no tRNA) is represented by (×).
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Surprisingly, we found no increase in complementation as the
nucleotides within the stem were made to correspond to the stem
region of E. coli tRNALys,3-MA (Fig. 3B). These mutants did
complement, but at levels similar to that for the unaltered E. coli
tRNALys,3. Thus, alteration of the nucleotides within the stem of
E. coli tRNALys,3 to correspond to that of E. coli tRNALys3-MA
did not impart the enhanced complementation observed with E.
coli tRNALys,3-MA.
Inspection of E. coli tRNALys,3-MA revealed an additional
nucleotide change in the variable loop at nucleotide 44. In E.
coli tRNALys,3, this nucleotide is a U while in mammalian
tRNALys,3 it is a G. To determine the effects of this single
nucleotide change, we constructed a mutant E. coli tRNALys,3 in
which the U was changed to a G (Fig. 4A). We then
characterized the capacity of this tRNA to complement the
HIV-1 proviral genome with a PBS complementary to E. coli
tRNALys,3. Analysis revealed that complementation was
slightly enhanced with the U44G mutation compared to the
complementation with a tRNA containing the stem identical to
mammalian tRNALys,3, though, the levels of complementation
did not reach that for E. coli tRNALys,3-MA (Fig. 4B).Collectively, the results of these studies demonstrate that the
capacity of E. coli tRNALys,3-MA to complement greater than
that observed for E. coli tRNALys,3 resides in the continuity of
the nucleotides within the variable loop and the stem of the
anticodon stem–loop.
Discussion
In the current study, we have utilized an in trans com-
plementation system to ascertain the importance of nucleo-
tides in tRNALys,3 for selection and use in HIV-1 reverse
transcription. Our experiments relied on the use of E. coli
tRNALys,3, which shares many features in common with
mammalian tRNALys,3. A major difference resides in the 3′
terminal 18-nucleotides, which interact with the HIV-1 PBS,
and the nucleotides within the anticodon stem of the tRNA.
Although E. coli tRNALys,3 can complement an HIV-1 proviral
genome in which the PBS was made complementary to the 3′
terminal 18-nucleotides of this tRNA, we found that the
complementation was enhanced if the nucleotides within the
variable region and the anticodon stem of E. coli tRNALys,3
were made to correspond to that of mammalian tRNALys,3 (E.
Fig. 4. Complementation of HXB2(EcPBSLys) with a plasmid that encodes E.
coli tRNALys,3G. (A) The anticodon stem–loop sequence of E. coli tRNALys,3
and E. coli tRNALys,3(G). The boldface and boxed nucleotide represents base
change made in E. coli tRNALys,3 sequence to match the sequence of
mammalian tRNALys,3. (B) Luciferase activity obtained from infection of
JC53-BL cells with viral supernatants obtained from co-transfections of
293HEK cells with 500 ng of proviral plasmids, and tRNA plasmids titrated
in at the designated quantities. Luciferase activity, in relative Light Units per mL
(rLU/mL), for complementation of plasmid HXB2(EcPBSLys) with pU6EcLys-
MA is represented by open diamonds (◊); for plasmid HXB2(EcPBSLys) with
pU6EcLys(G) is represented with closed squares (■); for plasmid HXB2
(EcPBSLys) with pU6EcLys(PsiCA) is represented with open squares (□). Wild-
type HXB2 (500 ng and no tRNA) is represented by (×). The data denote
means±standard deviations derived from three independent transfections.
Fig. 3. Complementation of HXB2(EcPBSLys) with a plasmid that encodes E.
coli tRNALys,3Psi and E. coli tRNALys,3PsiCA. (A) The anticodon stem–
loop sequence of E. coli tRNALys,3, E. coli tRNALys,3(Psi), and E. coli
tRNALys,3(PsiCA). The boldface and boxed nucleotides represent base changes
made in E. coli tRNALys,3 sequence to match the sequence of mammalian
tRNALys,3. (B) Luciferase activity obtained from infection of JC53-BL cells with
viral supernatants obtained from co-transfections of 293HEK cells with 500 ng
of proviral plasmids, and tRNA plasmids titrated in at the designated quantities.
Luciferase activity, in relative Light Units per mL (rLU/mL), for complementa-
tion of plasmid HXB2(EcPBSLys) with pU6EcLys-MA is represented by open
diamonds (◊); for plasmid HXB2(EcPBSLys) with pU6EcLys(Psi) is represented
with closed circles (●); for plasmid HXB2(EcPBSLys) with pU6EcLys(PsiCA) is
represented with open squares (□). Wild-type HXB2 (500 ng and no tRNA) is
represented by (×). The data denote means±standard deviations derived from
three independent transfections.
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nucleotides within the variable region and anticodon stem–
loop indicated that all changed nucleotides within the variable
and anticodon stem–loop were important for the enhanced
complementation observed with E. coli tRNALys,3-MA.
Previous studies have suggested that the RNA structures of
E. coli tRNALys,3 and mammalian tRNALys,3 are similar in the
anticodon region (Durant et al., 2005; Sprinzl et al., 1991;
Sudarsan et al., 2006; Yarian et al., 2000). Much of this is due to
analogous post-transcriptionally modified bases at positions 34
and 37, and a pseudouridine at position 39. Previous studies
from our group and others have shown that E. coli tRNALys,3
can be aminoacylated by mammalian lysyl-tRNA synthetase
(McClain et al., 1990; McCulley and Morrow, 2006; Stello et
al., 1999; Tamura et al., 1992). The major differences between
mammalian and E. coli tRNALys,3 reside in the nucleotides
sequence in the stem of the anticodon stem–loop. Thus, the
results of our studies to mutate nucleotides within the stem to
correspond to mammalian tRNALys,3 were surprising in that
they did not result in enhanced complementation by E. coli
tRNALys,3. In fact, the only mutation that generated an increasein complementation, albeit not at the level of E. coli tRNALys,3-
MA, was a mutation in the variable loop. Our results are
consistent with the idea that tRNALys,3 sequence UGAGGG is
important for tRNALys,3 to be effectively selected as the primer
for initiation of reverse transcription. Interestingly, this
sequence is involved in at least two interactions with the HIV-
1 genome (Fig. 5A). In the first, this sequence forms an
intermolecular interaction with the U5 region of the HIV-1 viral
genome within the tRNA U5 initiation complex (Isel et al.,
1993, 1996). To address this issue, we made additional
mutations in the HIV-1 proviral genome to compensate for
mismatched base pairs as a result of interaction with E. coli
tRNALys,3 (Fig. 5B). However, the complementation observed
for this virus with E. coli tRNALys,3 was not greater than that
found for E. coli tRNALys,3-MA with the wild-type virus,
suggesting that this interaction could not account for the
enhanced complementation observed in our study (data not
shown). Thus, we do not believe that the lower complementa-
tion of E. coli tRNALys,3 compared to tRNALys,3-MA was due
to the inability to interact with the U5 region. It is possible
though that the extensive refolding of tRNALys,3 required to
form the complex between tRNA:viral genome could have
Fig. 5. Mammalian tRNALys,3 and the corresponding potential interactions with the proviral U3 region. (A) The cloverleaf depiction of mammalian tRNALys,3 with
outlined anti-PBS region, which interacts with the PBS in the viral RNA genome, anti-U3 region, which interacts with the U3 region in the viral RNA genome, and
anti-A-loop region, which interacts with the A-rich loop in the viral RNA genome during reverse transcription. (B) Proposed interactions between HIV-1 (HXB2) and
E. coli tRNALys,3 based on Isel structure (Isel et al., 1993, 1996). Boxed bases represent E. coli tRNALys,3. Bolded nucleotides AAUU in E. coli tRNALys,3 proposed to
interact with HIV-1 genome in Isel structure; the circled nucleotides in HIV-1 genome were changed to promote Isel structure with E. coli tRNALys,3. However, HIV-1
genomes with these changes did not show enhanced complementation with E. coli tRNALys,3 (data not shown). The bold D in tRNALys,3 is in the D loop. (C) Schematic
of viral RNA anticodon tRNALys,3 interaction in the U3 region. The sequence fragment of the viral U3 RNA genome that base pairs with the stem and part of the
variable sequence found in the tRNALys,3. All nucleotides in mammalian tRNALys,3 and E. coli tRNALys,3-MA are complementary to the viral U3 RNA genome
sequence, whereas only 5 out of 9 nucleotides are complementary in E. coli tRNALys,3.
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tRNALys,3 and tRNALys,3-MA. Additional studies will be
required to test this possibility.
A second interaction between tRNALys,3 and the viral
genome has been shown from in vitro studies where
complementarity between the nucleotides in the anticodon
stem, part of the variable loop of tRNALys,3, and the U3
facilitated the first strand transfer of HIV-1 reverse transcription
(Brule et al., 2000). In this in vitro system, a several fold
enhancement of the strand transfer was observed using an in
vitro synthesized tRNA that had regions complementary to the
regions in U3. Interestingly, the nucleotides within the U3 arehighly conserved among all other lentiviruses. There are several
nucleotide mismatches between the E. coli tRNALys,3 and the
U3 sequence that might reduce the efficiency of strand transfer
and hence the production of infectious virus (Fig. 5C).
Alteration of the sequence to correspond to tRNALys,3-MA
provides complete sequence complementarity with the U3
region. However, it is not clear whether this interaction between
these specific nucleotides in U3 and tRNALys,3 is absolutely
required. For example, previous studies from this laboratory
have identified several tRNAs that can be stably utilized by HIV
if A-loop PBS modifications were made (Wakefield et al., 1996;
Zhang et al., 1998). One of these viruses, which was engineered
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loop to stably utilize this tRNA for reverse transcription. Brule
et al. found that a similar region within the viral RNA genome in
U3 is complementary to the sequences within tRNAHis, but was
not the same required for the interaction between U3 and
tRNALys,3 (Brule et al., 2000). Thus, HIV-1 that has been forced
to utilize tRNAHis by mutations within the PBS and A-loop
region might have evolved to alter nucleotides within U3 to
facilitate the first strand jump. Additional experiments will be
required to delineate the interaction between U3 and tRNALys,3
during reverse transcription.
Collectively, the results of these studies demonstrate a
dynamic relationship between the HIV-1 viral genome and the
host during acquisition of the primer utilized for virus
replication. The results of our studies are consistent with the
concept that HIV-1 has evolved to efficiently select and use
tRNALys,3 as the preferred primer through in part maximization
of tRNA:genome RNA interactions. To date, the 3′ terminal 18-
nucleotides, TΨC loop, and anticodon stem–loop region of
tRNALys,3 have been shown to be involved with the interaction
(Fig. 5A). Further studies using this unique in trans comple-
mentation system will allow elucidation of the interactions
between the tRNALys,3 and the viral genome required for the
preferential selection of tRNALys,3.
Materials and methods
Tissue culture
The 293HEK and JC53-BL cells were cultured in Dulbec-
co's modified Eagle's medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% antibiotic (Gibco/BRL,
Gaithersburg, MD.). Cell cultures were maintained in 37 °C
incubator supplemented with 5% CO2.
Proviral and tRNA plasmids
The proviral plasmid encoding the full length HXB2 with a
PBS altered to be complementary to the 3′-terminal 18-
nucleotides of E. coli tRNALys,3 and the E. coli tRNALys gene
was constructed previously (McCulley and Morrow, 2006).
The E. coli tRNALys,3(A73G), E. coli tRNALys,3(MA), E. coli
tRNALys,3(PsiCA), E. coli tRNALys,3(Psi), and E. coli
tRNALys,3(G) were prepared by PCR extension with the use
of the following primers: (forward A73G) GCAGGGCTCG-
AGGTCCGGGTCGTTAGCTCAGTTGGTAGAGCAGTT-
GACTTTTAATCAATTGGTCGCAGG3′, (reverse A73G)
GCGGACGAAGCTTCCAAAAAACGGGTCGTGCAG-
GACTTGAACCTGCGACCAATTGATTAAAAGTCAA3′;
(forward MA) 5′GCAGGGCTCGAGGTCCGGGTCGT-
TAGCTCAGTCGGTAGAGCATCAGACTTTTAATCT-
GAGGGTCGCAGG3′, (reverse MA) 5′GCGGACGAAGC-
TTCCAAAAAATGGGTCGTGCAGGACTTGAACCTGC-
GACCCTCAGATTAAAAGTCTG3′; (forward PsiCA) 5′
GCAGGGCTCGAGGTCCGGGTCGTTAGCTCAGTTGG-
TAGAGCATCAGACTTTTAATCTGATGGTCGCAGG3′,
(reverse PsiCA) 5′GCGGACGAAGCTTCCAAAAAATGGG-TCGTGCAGGACTTGAACCTGCGACCATCAGAT-
TAAAAGTCTGATG3′; (forward Psi) 5′GCAGGGCTC-
GAGGTCCGGGTCGTTAGCTCAGTTGGTAGAGCATTT-
GACTTTTAATCAAATGGTCGCAGG3′, (reverse Psi) 5′
GCGGACGAAGCTTCCAAAAAATGGGTCGTGCAG-
GACTTGAACCTGCGACCATTTGATTAAAAGT-
CAAATG3′; (forward U43G) 5′GCAGGGCTCGAGGTCC-
GGGTCGTTAGCTCAGTTGGTAGAGCAGTTGAC-
TTTTAATCAATGGGTCGCAGG3′, (reverse U43G) 5′
GCGGACGAAGCTTCCAAAAAATGGGTCGTGCAG-
GACTTGAACCTGCGACCCATTGATTAAAAGT-
CAACTG3′. The PCR products were TA cloned into pGEM
T-Easy vector (Promega, Madison, WI), and the resultant TA
clones were digested using XhoI andHindIII restriction enzymes
in order to release the E. coli tRNALys constructs (approximately
100-bp). Subsequently, the E. coli tRNALys constructs were
ligated into an LS9 plasmid upstream of a polymerase III
promoter using the XhoI and HindIII restriction sites (Kelly and
Morrow, 2003, 2005; Kelly et al., 2003). The end products
resulted in plasmids labeled pU6EcLys(A73G), pU6EcLys(MA),
pU6EcLys(PsiCA), pU6EcLys(Psi), and pU6EcLys(U43G). All
plasmids were screened with enzyme restriction and verified by
DNA sequencing.
Co-transfections
Complementation of HIV-1 proviral mutants was performed
in a previously described manner (McCulley and Morrow,
2006). Briefly, 293HEK cells were co-transfected with tRNA-
carrying plasmids and HIV-1 proviral mutants 24 h after
seeding in 6-well plates. Transfections were achieved using a
calcium-phosphate method previously described (Jordan et al.,
1996). The cells were co-transfected with 500 ng of proviral
plasmid and 100 ng, 500 ng, 1000 ng, and 1500 ng of tRNA-
carrying plasmid. Mock and control (proviral plasmids alone, or
tRNA plasmids alone) transfections were also included.
Approximately 7 h after co-transfection, the cells were washed
once with 1× PBS and replenished with fresh media.
Approximately 48 h post-transfection, supernatants were
collected, centrifuged at 3000×g, and serially diluted for
infection of JC53-BL cells.
JC53-BL Infections
Supernatants collected from co-transfections were used in
JC53-BL reporter assay in order to determine infectious viral
units from luciferase activity (Wei et al., 2002). JC53-BL assay
was performed as described previously (McCulley and Morrow,
2006). Briefly, supernatants were diluted 1:3 in DMEM
supplemented with 2% FBS, followed by two sequential 1:5
dilutions, and used to infect JC53-BL cells that were seeded
24 h pre-infection. JC53-BL cells with the added supernatants
were incubated for 2 h in a 37 °C incubator supplemented with
5% CO2. After 2 h, DMEM supplemented with 10% FBS was
added to each well and the cells were incubated for additional
48 h. To determine luciferase activity, cells were lysed using M-
PER Mammalian Protein Extraction Reagent (PIERCE,
176 A. McCulley, C.D. Morrow / Virology 364 (2007) 169–177Rockford, IL) and approximately 20 μL of each sample was
transferred to a microplate. Reporter Lysis Buffer (Promega,
Madison, WI) was added to each sample in the microplate and
the light intensity was measured using a Tropix TR717
Microplate Luminometer (Applied Biosystems, Foster City,
CA). Wells that contained lysed samples from uninfected cells
represented background and the luciferase activity obtained
from these wells was subtracted from all other samples.
Luciferase activity for pHXB2(EcPBSLys), without the com-
plementing tRNA, was set as background also. The difference
obtained from subtracting luciferase activity values of unin-
fected samples from luciferase activity values of pHXB2
(EcPBSLys), without the complementing tRNA, was subtracted
from all complementation samples. The luciferase activity
values of two dilutions per sample were averaged. Relative
Light Units (rLU) per mL were calculated by dividing the
luciferase activity values by their corresponding dilutions.
RNA isolation and tRNA analysis
293HEK cells were transfected with pU6EcLys, pU6EcLys
(A73G), pU6EcLys(MA), pU6EcLys(PsiCA), pU6EcLys(Psi),
and pU6EcLys(U43G) using calcium phosphate via a previously
described method (Jordan et al., 1996). Aminoacyl tRNAs were
collected approximately 48 h post-transfection. Collection and
isolation of aminoacylated tRNAs were performed as pre-
viously described (Kelly and Morrow, 2003, 2005; Kelly et al.,
2003; McCulley and Morrow, 2006). Aminoacyl tRNAs were
also isolated from mock-transfected 293HEK cells. All E. coli
tRNALys molecules were detected using a [γ-32P] ATP kinased
oligo, 5′GGTCGTGCAGGATTCGAACCTGCGACCAA3′,
that was labeled with the use of Ready-to-go T4 polynucleotide
kinase (Amersham Pharmacia Biotech, Piscataway, NJ).
Aminoacyl tRNAs were separated based on charge using an
acidic polyacrylamide gel and analyzed using Northern blotting
(Kelly and Morrow, 2003, 2005; Kelly et al., 2003; McCulley
and Morrow, 2006). X-ray film was exposed to the probed
membranes and developed using the SRX-101A developer
(Konica, Wayne, NJ).
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